Atypia of undetermined significance and ThyroSeq v3–positive call rates as quality control metrics for cytology laboratory performance

IF 2.6 3区 医学 Q3 ONCOLOGY Cancer Cytopathology Pub Date : 2024-04-09 DOI:10.1002/cncy.22821
Odille Mejia-Mejia MD, Andres Bravo-Gonzalez MD, Monica Sanchez-Avila MD, Youley Tjendra MD, Rodrigo Santoscoy MD, Katherine Drews-Elger MD PhD, Yiqin Zuo MD PhD, Camilo Arias-Abad PhD, Carmen Gomez MD, Monica Garcia-Buitrago MD, Mehrdad Nadji MD, Merce Jorda MD PhD MBA, Jaylou M. Velez-Torres MD, Roberto Ruiz-Cordero MD
{"title":"Atypia of undetermined significance and ThyroSeq v3–positive call rates as quality control metrics for cytology laboratory performance","authors":"Odille Mejia-Mejia MD,&nbsp;Andres Bravo-Gonzalez MD,&nbsp;Monica Sanchez-Avila MD,&nbsp;Youley Tjendra MD,&nbsp;Rodrigo Santoscoy MD,&nbsp;Katherine Drews-Elger MD PhD,&nbsp;Yiqin Zuo MD PhD,&nbsp;Camilo Arias-Abad PhD,&nbsp;Carmen Gomez MD,&nbsp;Monica Garcia-Buitrago MD,&nbsp;Mehrdad Nadji MD,&nbsp;Merce Jorda MD PhD MBA,&nbsp;Jaylou M. Velez-Torres MD,&nbsp;Roberto Ruiz-Cordero MD","doi":"10.1002/cncy.22821","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) recommends an upper limit of 10% for atypia of undetermined significance (AUS). Recent data suggest that this category might be overused when the rate of cases with molecular positive results is low. As a quality metric, the AUS and positive call rates for this facility’s cytology laboratory and each cytopathologist (CP) were calculated.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A retrospective analysis of all thyroid cytology cases in a 4.5-year period was performed. Cases were stratified by TBSRTC, and molecular testing results were collected for indeterminate categories. The AUS rate was calculated for each CP and the laboratory. The molecular positive call rate (PCR) was calculated with and without the addition of currently negative to the positive results obtained from the ThyroSeq report.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 7535 cases were classified as nondiagnostic, 7.6%; benign, 69%; AUS, 17.5%; follicular neoplasm/suspicious for follicular neoplasm, 1.4%; suspicious for malignancy, 0.7%; and malignant, 3.8%. The AUS rate for each CP ranged from 9.9% to 36.8%. The overall PCR was 24% (range, 13%–35.6% per CP). When including cases with currently negative results, the PCR increased to 35.5% for the cytology laboratory (range, 13%–42.6% per CP). Comparison analysis indicates a combination of overcalling benign cases and, less frequently, undercalling of higher TBSRTC category cases.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The AUS rate in the context of PCR is a useful metric to assess cytology laboratory and cytopathologists’ performance. Continuous feedback on this metric could help improve the overall quality of reporting thyroid cytology.</p>\n </section>\n </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 8","pages":"481-490"},"PeriodicalIF":2.6000,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22821","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cytopathology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cncy.22821","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) recommends an upper limit of 10% for atypia of undetermined significance (AUS). Recent data suggest that this category might be overused when the rate of cases with molecular positive results is low. As a quality metric, the AUS and positive call rates for this facility’s cytology laboratory and each cytopathologist (CP) were calculated.

Methods

A retrospective analysis of all thyroid cytology cases in a 4.5-year period was performed. Cases were stratified by TBSRTC, and molecular testing results were collected for indeterminate categories. The AUS rate was calculated for each CP and the laboratory. The molecular positive call rate (PCR) was calculated with and without the addition of currently negative to the positive results obtained from the ThyroSeq report.

Results

A total of 7535 cases were classified as nondiagnostic, 7.6%; benign, 69%; AUS, 17.5%; follicular neoplasm/suspicious for follicular neoplasm, 1.4%; suspicious for malignancy, 0.7%; and malignant, 3.8%. The AUS rate for each CP ranged from 9.9% to 36.8%. The overall PCR was 24% (range, 13%–35.6% per CP). When including cases with currently negative results, the PCR increased to 35.5% for the cytology laboratory (range, 13%–42.6% per CP). Comparison analysis indicates a combination of overcalling benign cases and, less frequently, undercalling of higher TBSRTC category cases.

Conclusions

The AUS rate in the context of PCR is a useful metric to assess cytology laboratory and cytopathologists’ performance. Continuous feedback on this metric could help improve the overall quality of reporting thyroid cytology.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
将意义未定的不典型性和 ThyroSeq v3 阳性调用率作为细胞学实验室绩效的质量控制指标
背景贝塞斯达甲状腺细胞病理学报告系统(TBSRTC)建议,意义未定的不典型性(AUS)的上限为 10%。最近的数据表明,当分子检测结果呈阳性的病例比例较低时,这一类别可能会被过度使用。作为一项质量指标,我们计算了该机构细胞学实验室和每位细胞病理学家(CP)的 AUS 和阳性病例率。方法我们对 4.5 年内的所有甲状腺细胞学病例进行了回顾性分析。根据 TBSRTC 对病例进行了分层,并收集了不确定类别的分子检测结果。计算了每个 CP 和实验室的 AUS 率。结果共有 7535 例病例被归类为:无诊断率 7.6%;良性 69%;AUS 17.5%;滤泡性肿瘤/可疑滤泡性肿瘤 1.4%;可疑恶性 0.7%;恶性 3.8%。每种 CP 的 AUS 率从 9.9% 到 36.8% 不等。总体 PCR 为 24%(每个 CP 的范围为 13%-35.6%)。如果将目前结果为阴性的病例包括在内,细胞学实验室的 PCR 增至 35.5%(每 CP 的范围为 13%-42.6%)。对比分析表明,良性病例的漏检率较高,而TBSRTC类别较高的病例漏检率较低。对这一指标的持续反馈有助于提高甲状腺细胞学报告的整体质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer Cytopathology
Cancer Cytopathology 医学-病理学
CiteScore
7.00
自引率
17.60%
发文量
130
审稿时长
1 months
期刊介绍: Cancer Cytopathology provides a unique forum for interaction and dissemination of original research and educational information relevant to the practice of cytopathology and its related oncologic disciplines. The journal strives to have a positive effect on cancer prevention, early detection, diagnosis, and cure by the publication of high-quality content. The mission of Cancer Cytopathology is to present and inform readers of new applications, technological advances, cutting-edge research, novel applications of molecular techniques, and relevant review articles related to cytopathology.
期刊最新文献
Cytologic diagnosis of fumarate hydratase-deficient renal cell carcinoma: A single-institutional experience. Mucinous-appearing contamination of serous effusions by sodium carboxymethyl cellulose from suction canister lids. Intraoperative peritoneal cytology for cervical gastric-type adenocarcinoma: Cytopathology and clinical impact. Single-cell multiplex immunocytochemistry in cell block preparations of metastatic breast cancer confirms sensitivity of GATA-binding protein 3 over gross cystic disease fluid protein 15 and mammaglobin. International perspective on pediatric cytology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1